PWA
TXMD icon

Provenance Wealth Advisors’s TherapeuticsMD TXMD Stock Holding History

Provenance Wealth Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44 Hold
20
– – ﹤0.01% 608
2026
Q1 		$40 Hold
20
– – ﹤0.01% 411
2025
Q4 		$33 Hold
20
– – ﹤0.01% 418
2025
Q3 		$22 Hold
20
– – ﹤0.01% 436
2025
Q2 		$23 Hold
20
– – ﹤0.01% 420
2025
Q1 		$19 Hold
20
– – ﹤0.01% 539
2024
Q4 		$17 Hold
20
– – ﹤0.01% 554
2024
Q3 		$33 Hold
20
– – ﹤0.01% 597
2024
Q2 		$32 Hold
20
– – ﹤0.01% 515
2024
Q1 		$46 Hold
20
– – ﹤0.01% 541
2023
Q4 		$45 Hold
20
– – ﹤0.01% 593
2023
Q3 		$60 Buy
+20
New +$76 ﹤0.01% 481

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Provenance Wealth Advisors's TXMD Position: Q2 2026 in Review

Provenance Wealth Advisors held its TherapeuticsMD (TXMD) position steady in Q2 2026 at 20 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Provenance Wealth Advisors first reported a position in TXMD in Q3 2023 and has held it in 12 quarters since. The position peaked at $60 in Q3 2023. 44 funds tracked by Wall St. Rank hold TXMD as of Q2 2026.

  • Provenance Wealth Advisors held 20 shares of TherapeuticsMD worth $44 as of Q2 2026.
  • Provenance Wealth Advisors left its TherapeuticsMD share count unchanged in Q2 2026.
  • TherapeuticsMD made up ﹤0.01% of Provenance Wealth Advisors's portfolio in Q2 2026, its #608 holding.
  • Provenance Wealth Advisors first reported a position in TherapeuticsMD in Q3 2023 and has held it in 12 quarters since.
  • Provenance Wealth Advisors's TherapeuticsMD position peaked at $60 in Q3 2023.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.